EQS-News: Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024
EQS-News: Marinomed Biotech AG / Key word(s): Market Launch
Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024
15.06.2023 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.
═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024
• Moisturizing eye drops complement existing Carragelose OTC product portfolio
• Benefits of Carragelose extended to application in the eye
• Single-territory test launch in Austria in preparation for 2024 and business development process for international roll-out initiated
Korneuburg, Austria, 15 June 2023 – Marinomed Biotech AG (VSE:MARI), announced today the introduction of a new Carragelose eye drop product (MAM-1001-3), expanding
the range of the marketed Carragelose OTC portfolio. The product has a valid certification under the Medical Device Directive (MDD) and is currently being prepared
for marketing. With a clear path to certify the eye drops under the new Medical Device Regulation (MDR), including the planning of a clinical trial, the product is
ready for partnering and distribution in the EU. With a first partnership for the eye drops already in place, a market launch in Austria is targeted for the first
half of 2024. Further, Marinomed has started a business development process to identify further partners for the marketing of the product worldwide.
“The introduction of Carragelose eye drops is a logical addition to our current OTC portfolio. This asset has an upright certification and is ready for partnering
and marketing, thus will be generating revenues in the near to medium term,” explains Andreas Grassauer, CEO of Marinomed. “The product is intended to provide
relief for dry eyes. Carragelose has excellent moisturizing properties and an outstanding safety profile. In addition, Carragelose is well known for its
virus-blocking effectiveness.”
About Carragelose®:
Carragelose® is a sulfated polymer from red seaweed and a unique, broadly active virus-blocking compound. It is known as a gentle, effective, and safe prevention
and treatment of various viral respiratory infections. Several clinical and preclinical studies have shown that Carragelose® forms a protective layer on the mucosa
that prevents viruses from infecting cells. Laboratory and clinical data have demonstrated that Carragelose® can also inhibit the spreading of
SARS-CoV-2.[1]^[1],[2]^[2] Marinomed is the holder of the IP rights and has licensed Carragelose® for marketing in Europe, North America, Australia, and parts of
Asia and Latin America. Marinomed’s portfolio of Carragelose®-containing nasal sprays and oral products can be accessed at
[3] https://www.carragelose.com/en/portfolio/launched-products, scientific publications on Carragelose® at [4] https://www.carragelose.com/en/publications.
About Marinomed Biotech AG:
Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops
innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of
iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections
that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange
(VSE:MARI). For further information, please visit: [5] https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG International Media Contact
PR: Lucia Ziegler Metrum Communications: Roland Mayrl
T: +43 2262 90300 158 T: +43 664 6126228
E-Mail: [6]pr@marinomed.com E-Mail: [8]marinomed@metrum.at
IR: Stephanie Kniep
T: +43 2262 90300 226
E-Mail: [7]ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG
about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to
differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of
Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”,
“project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update,
review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.
Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.
[9]^[1] [10]https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM
[11]^[2]
[12]https://www.marinomed.com/en/news/marinomed-biotech-ag-shares-positive-clinical-trial-results-for-iota-carrageenan-nasal-spray-in-the-prevention-of-covid-19-1
═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
15.06.2023 CET/CEST This Corporate News was distributed by EQS Group AG. www.eqs.com
═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 1656925
End of News EQS News Service
1656925 15.06.2023 CET/CEST
References
Visible links
1. file:///tmp/HTML-FormatExternal-dNOvt6.html#_edn1
2. file:///tmp/HTML-FormatExternal-dNOvt6.html#_edn2
3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=bd2a3dda556ab52fe6b2a10b732e7834&application_id=1656925&site_id=apa_ots_austria&application_name=news
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=43c84c05c837223116d24f9889459559&application_id=1656925&site_id=apa_ots_austria&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=1656925&site_id=apa_ots_austria&application_name=news
6. pr@marinomed.com
7. ir@marinomed.com
8. marinomed@metrum.at
9. file:///tmp/HTML-FormatExternal-dNOvt6.html#_ednref1
10. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=33ccd3741e11d696674979569046f638&application_id=1656925&site_id=apa_ots_austria&application_name=news
11. file:///tmp/HTML-FormatExternal-dNOvt6.html#_ednref2
12. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=21dfc7afdd676fd13f5e421e04701661&application_id=1656925&site_id=apa_ots_austria&application_name=news
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender